
Non-Sponsored Content
Iobenguane I-131 FDA approved for rare adrenal neuroendocrine tumours
By: News Feed | Last updated: 31st July 2018 | In: Oncology, Radioactive Drugs, US FDA Onc\Haem Approvals
Article Keywords
Azedra, FDA, iobenguane I-131, paediatric, paraganglioma, pheochromocytoma, PPGL, Progenics Pharmaceuticals
On July 30, 2018, the FDA approved iobenguane I-131 (Azedra®, Progenics Pharmaceuticals), a radioactive therapeutic agent, for the treatment of adult and paediatric patients ≥12 years with iobenguane scan positive, locally advanced or metastatic pheochromocytoma or paraganglioma (PPGL) not amenable to surgery and indicated for systemic therapy.
Study IB12B
The FDA based her opinion on the open-label, single-arm, multicentre Study IB12B (NCT00874614) in patients ≥12 years. Participants with an iobenguane scan-positive, unresectable, locally advanced or metastatic PPGL were eligible for participation. A reduction of ≥50% of all antihypertensive medication for ≥6 months was observed in 17 (25%; 95% CI, 16-37%) of the 68 evaluable patients. A tumour response by RECIST 1.0 was recorded in 15 (22%; 95% CI, 14-33%) patients. A duration of response ≥6 months was noted in 53% of the responders.
Safety
Common grade 3-4 adverse reactions occurring in ≥10% of patients in the Study IB12B included lymphopenia, neutropenia, thrombocytopenia, fatigue, anaemia, increased international normalised ratio (INR), nausea, dizziness, hypertension, and vomiting. Myelodysplastic syndrome or acute leukaemia was observed in 6.8% of patients who received a therapeutic dose of iobenguane I-131 (pooled safety population).
Disclaimer
This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).
© Copyright 2018 MediPaper Medical Communications Ltd.
YOU MAY ALSO LIKE




































































Venetoclax plus azacitidine, decitabine, or low-dose cytarabine FDA approved in elderly AML patients











































































































© Copyright 2018 MediPaper Medical Communications Ltd.
Leave a Reply
Want to join the discussion?Feel free to contribute!